Nuvalent, Inc.

Subsidiary of GlaxoSmithKline (GSK)

Assets

(3 total)
3Total Assets
1Approved
1Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 3 of 3 assets
Target & Modality
Approved
ROS1Small molecule
Non-Small Cell Lung Cancer
ROS1-Positive Non-Small Cell Lung Cancer
Phase 3
ALKSmall molecule
Non-Small Cell Lung Cancer
ALK-Positive Non-Small Cell Lung Cancer
Phase 1
HER2Small molecule
Non-Small Cell Lung Cancer
HER2-Mutant Non-Small Cell Lung Cancer

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
December 2027 (2)
neladalkibPhase 1/2Locally Advanced Solid Tumor, Metastatic Solid Tumor
Est. primary completion 2027-12 · NCT05384626 · CT.gov ↗
What to watch
ZidesamtinibPhase 1/2Locally Advanced Solid Tumor, Metastatic Solid Tumor
Est. primary completion 2027-12-31 · NCT05118789 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
neladalkibPhase 3Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
Est. primary completion 2029-12 · NCT06765109 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(7)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

27 November 2026FDA action dateneladalkibFDA accepts neladalkib NDA with Priority Review; PDUFA date 2026-11-27
US, FDA · Nuvalent, Inc. · Source ↗

Recent

18 September 2026FDA action dateZidesamtinibPDUFA target action date set for September 18, 2026
US, FDA · Source ↗
22 July 2026ApprovalZidesamtinibFDA approves Jideytro (zidesamtinib) in ROS1-positive NSCLC
US, FDA · Source ↗
7 April 2026Filing submittedneladalkibNDA submitted to FDA for neladalkib
US, FDA · Source ↗
19 November 2025Filing acceptedZidesamtinibFDA accepts zidesamtinib NDA for TKI pre-treated ROS1-positive NSCLC
US, FDA · Source ↗
17 November 2025Topline resultneladalkibALKOVE-1 pivotal data for neladalkib in TKI pre-treated ALK-positive NSCLC: ORR 31%
Nuvalent, Inc. · Source ↗
24 June 2025Topline resultZidesamtinibPositive pivotal ARROS-1 data in TKI pre-treated ROS1+ NSCLC

Financial reports

Quarterly & interim (14)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$84M$160M+ $1.1B short-term inv.$109M-$92M operating cash flowreport ↗
View 13 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3—$84M$116M+ $827M short-term inv.$122M-$70M operating cash flowreport ↗
2025-Q2—$81M$127M+ $878M short-term inv.$100M-$77M operating cash flowreport ↗
2025-Q1—$74M$121M+ $952M short-term inv.$85M-$55M operating cash flowreport ↗
2024-Q3—$61M$369M+ $799M short-term inv.$84M-$46M operating cash flowreport ↗
2024-Q2—$49M$78M+ $580M short-term inv.$57M-$41M operating cash flowreport ↗
2024-Q1—$39M$99M+ $593M short-term inv.$44M-$36M operating cash flowreport ↗
2023-Q3—$30M$88M+ $325M short-term inv.$34M-$23M operating cash flowreport ↗
2023-Q2—$26M$71M+ $360M short-term inv.$29M-$22M operating cash flowreport ↗
2023-Q1—$22M$90M+ $360M short-term inv.$25M-$24M operating cash flowreport ↗
2022-Q3—$15M$76M+ $164M short-term inv.$20M-$18M operating cash flowreport ↗
2022-Q2—$14M$76M+ $181M short-term inv.$18M-$15M operating cash flowreport ↗
2022-Q1—$13M$67M+ $205M short-term inv.$18M-$14M operating cash flowreport ↗
2021-Q3—$9.1M$246M+ $57M short-term inv.$12M-$11M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$307M$262M+ $1.1B short-term inv.$425M-$275M operating cash flowreport ↗

Nuvalent, Inc. reported R&D spend of $306.97M, up 41.0% YoY, cash and equivalents of $261.75M, and a quarterly net burn of $425.38M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$218M$146M+ $973M short-term inv.$261M-$185M operating cash flowreport ↗
2023-FY—$113M$335M+ $385M short-term inv.$126M-$100M operating cash flowreport ↗
2022-FY—$64M$242M+ $230M short-term inv.$82M-$65M operating cash flowreport ↗
2021-FY—$36M$69M+ $220M short-term inv.$46M-$40M operating cash flowreport ↗